Takara L Stanley1, Lindsay T Fourman1, Isabel Zheng1, Colin M McClure1, Meghan N Feldpausch1, Martin Torriani2, Kathleen E Corey3, Raymond T Chung3, Hang Lee4, David E Kleiner5, Colleen M Hadigan6, Steven K Grinspoon1. 1. Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 2. Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 3. Liver Center, Gastroenterology Division, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 4. Biostatistics Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 5. Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. 6. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Abstract
CONTEXT: Growth hormone (GH) and IGF-1 help regulate hepatic glucose and lipid metabolism, and reductions in these hormones may contribute to development of nonalcoholic fatty liver disease (NAFLD). OBJECTIVE: To assess relationships between hepatic expression of IGF1 and IGF-binding proteins (IGFBPs) and measures of glycemia and liver disease in adults with NAFLD. Secondarily to assess effects of GH-releasing hormone (GHRH) on circulating IGFBPs. DESIGN: Analysis of data from a randomized clinical trial of GHRH. SETTING: Two US academic medical centers. PARTICIPANTS: Participants were 61 men and women 18 to 70 years of age with HIV-infection, ≥5% hepatic fat fraction, including 39 with RNA-Seq data from liver biopsy. MAIN OUTCOME MEASURES: Hepatic steatosis, inflammation, and fibrosis by histopathology and measures of glucose homeostasis. RESULTS: Hepatic IGF1 mRNA was significantly lower in individuals with higher steatosis and NAFLD Activity Score (NAS) and was inversely related to glucose parameters, independent of circulating IGF-1. Among the IGFBPs, IGFBP2 and IGFBP4 were lower and IGFBP6 and IGFBP7 (also known as IGFBP-related protein 1) were higher with increasing steatosis. Hepatic IGFBP6 and IGFBP7 mRNA levels were positively associated with NAS. IGFBP7 mRNA increased with increasing fibrosis. Hepatic IGFBP1 mRNA was inversely associated with glycemia and insulin resistance, with opposite relationships present for IGFBP3 and IGFBP7. GHRH increased circulating IGFBP-1 and IGFBP-3, but decreased IGFBP-2 and IGFBP-6. CONCLUSIONS: These data demonstrate novel relationships of IGF-1 and IGFBPs with NAFLD severity and glucose control, with divergent roles seen for different IGFBPs. Moreover, the data provide new information on the complex effects of GHRH on IGFBPs.
CONTEXT: Growth hormone (GH) and IGF-1 help regulate hepatic glucose and lipid metabolism, and reductions in these hormones may contribute to development of nonalcoholic fatty liver disease (NAFLD). OBJECTIVE: To assess relationships between hepatic expression of IGF1 and IGF-binding proteins (IGFBPs) and measures of glycemia and liver disease in adults with NAFLD. Secondarily to assess effects of GH-releasing hormone (GHRH) on circulating IGFBPs. DESIGN: Analysis of data from a randomized clinical trial of GHRH. SETTING: Two US academic medical centers. PARTICIPANTS: Participants were 61 men and women 18 to 70 years of age with HIV-infection, ≥5% hepatic fat fraction, including 39 with RNA-Seq data from liver biopsy. MAIN OUTCOME MEASURES: Hepatic steatosis, inflammation, and fibrosis by histopathology and measures of glucose homeostasis. RESULTS: Hepatic IGF1 mRNA was significantly lower in individuals with higher steatosis and NAFLD Activity Score (NAS) and was inversely related to glucose parameters, independent of circulating IGF-1. Among the IGFBPs, IGFBP2 and IGFBP4 were lower and IGFBP6 and IGFBP7 (also known as IGFBP-related protein 1) were higher with increasing steatosis. Hepatic IGFBP6 and IGFBP7 mRNA levels were positively associated with NAS. IGFBP7 mRNA increased with increasing fibrosis. Hepatic IGFBP1 mRNA was inversely associated with glycemia and insulin resistance, with opposite relationships present for IGFBP3 and IGFBP7. GHRH increased circulating IGFBP-1 and IGFBP-3, but decreased IGFBP-2 and IGFBP-6. CONCLUSIONS: These data demonstrate novel relationships of IGF-1 and IGFBPs with NAFLD severity and glucose control, with divergent roles seen for different IGFBPs. Moreover, the data provide new information on the complex effects of GHRH on IGFBPs.
Authors: Takara L Stanley; Lindsay T Fourman; Meghan N Feldpausch; Julia Purdy; Isabel Zheng; Chelsea S Pan; Julia Aepfelbacher; Colleen Buckless; Andrew Tsao; Anela Kellogg; Karen Branch; Hang Lee; Chia-Ying Liu; Kathleen E Corey; Raymond T Chung; Martin Torriani; David E Kleiner; Colleen M Hadigan; Steven K Grinspoon Journal: Lancet HIV Date: 2019-10-11 Impact factor: 12.767
Authors: Mabel Toribio; Kathleen V Fitch; Lauren Stone; Markella V Zanni; Janet Lo; Chris de Filippi; Craig A Sponseller; Hang Lee; Ida Grundberg; Melanie A Thompson; Judith A Aberg; Steven K Grinspoon Journal: EBioMedicine Date: 2018-08-31 Impact factor: 8.143
Authors: Matthew G Engel; Jeremy Smith; Kai Mao; Gabriela Farias Quipildor; Min-Hui Cui; Maria Gulinello; Craig A Branch; Samuel E Gandy; Derek M Huffman Journal: Geroscience Date: 2022-07-08 Impact factor: 7.581
Authors: Christoffer A Hagemann; Christian Legart; Mathias B Møllerhøj; Martin R Madsen; Henrik H Hansen; Merete J Kønig; Frederik Helgstrand; Flemming P Hjørne; Anders Toxværd; Jill L Langhoff; Urd L Kielgast; Lise L Gluud; Helene Ægidius; Kristoffer T G Rigbolt; Tina Vilsbøll; Jacob Jelsing; Filip K Knop Journal: PLoS One Date: 2022-10-19 Impact factor: 3.752